1526MO GEMMK: A phase I study of gemcitabine (gem) and pembrolizumab (pem) in patients (pts) with leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma UPS)

Autor:	Smrke, A., Ostler, A., Napolitano, A., Vergnano, M., Asare, B., Fotiadis, N., Thway, K., Zaidi, S., Miah, A.B., van der Graaf, W., Gennatas, S., Benson, C., Huang, P.H., Jones, R.L.
Zdroj:	In Annals of Oncology September 2021 32 Supplement 5:S1114-S1114
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu